Terry G. Mahn | Fish & Richardson P.C.
Hatch-Waxman turns 30 this year. One measure of its success has been the phenomenal growth and universal acceptance of generic drugs, which now account for over 80% of all prescriptions filled in the U.S. While much of the industry’s success was designed to come at the expense of pioneer drug developers, some clearly was unintended. One example how Hatch-Waxman has unexpectedly titled the balance in favor of generics is the evolution of FDA policies toward method of use patents.
Continue reading "Drug Labeling Games – Skinny Labels Getting an FDA Assist"
In The Headlines
Daniel Draz | Fraud Solutions
Two of the most often asked questions by businesses looking to gage their fraud risk management efforts are “how do we know if we’re adequately prepared for investigations and audits,” and “are we doing the right things?” The reality is that your company shouldn’t be waiting for investigations or audits to occur to determine how fit you are to deal with major fraud, compliance or regulatory related events.
Continue reading "Fraud Readiness: Is Your Company Fraud Fit or Ready to Flat Line?"
Topic of Discussion
Joanna Belbey | Actiance
Social media and the pharmaceutical and biotechnology industries are not known to be comfortable bed fellows.
According to a report released by the IMS Institute for Healthcare Informatics, only half of the top 50 pharmaceutical companies worldwide actively participate in social media on Facebook, Twitter or YouTube. And only 10 of these companies utilize all three of these major social networking services for healthcare topics, and then mainly as a unilateral broadcasting channel to physicians and patients, rather than fostering interactions or discussions.
Continue reading "Make Your First Step into Social the Right One"
Fish & Richardson Presents: Around the World in 60 Minutes: A Global Update on Recent Anticorruption Enforcement Efforts.
On January 15, Fish & Richardson presented its fourth event in its INSIGHTS webinar series, Around the World in 60 Minutes: A Global Update on Recent Anticorruption Enforcement Efforts. This FCPA impact webinar focused on the life sciences and pharmaceutical industries. Watch the replay.
The rise in high-dollar anticorruption actions has sparked a worldwide interest in enforcement that goes far beyond the FCPA and leaves companies to navigate a swiftly changing landscape of laws and regulations.
During this webinar, Fish’s Principals and prominent white collar defense attorneys Tom Frongillo and Bill Mateja explored key anticorruption trends and developments in various countries with. These former federal prosecutors identified issues that are particularly important for life sciences and pharmaceutical companies.
Specifically, the presenters discussed following topics:
- New developments under the U.K. Bribery Act, Brazil’s recent anticorruption law, and China’s domestic anti-bribery enforcement;
- 2013 enforcement efforts from other countries;
- A preview of which countries are looking to ramp-up anticorruption efforts in the upcoming year; and
- What you can do now to ensure that your compliance program is up to par.
If you oversee fraud investigations or have an interest in anticorruption or white collar criminal investigations, prosecutions, and case developments, you’ll want to watch the replay.
If you have questions about the webinar or want to be notified about future events, please contact Ellen Makarevich at firstname.lastname@example.org.
The complimentary INSIGHTS webinar series explores cases and trends that shape the legal landscape and provide a window into the ways Fish & Richardson attorneys think about these developments to formulate crucial legal strategies. Webinar replays are available within 48 hours after live delivery.
Fish & Richardson is a global law firm providing strategic counseling and litigation services to innovative clients who seek to protect and maximize the value of their intellectual property (IP). Founded in 1878, Fish’s early clients included Alexander Graham Bell, Thomas Edison and the Wright Brothers. The firm has more than 400 attorneys and technology specialists practicing IP strategy and counseling, IP litigation, and commercial litigation. Fish is consistently singled out for its superior technical expertise and great results, and has been named the top patent litigation firm in the country for ten consecutive years, the number one IP firm for America’s biggest companies, and an elite top tier law practice. For more information, visit fr.com and fishlitigationblog.com, and follow @fishrichardson and @fishlitigation on Twitter.